Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Array BioPharma (ARRY) PT Raised to $20 at Leerink Partners
February 7, 2018 7:40 AM ESTLeerink Partners raised its price target on Array BioPharma (NASDAQ: ARRY) to $20.00 (from $19.00) while maintaining a Outperform rating.
... MoreArray BioPharma (ARRY) PT Raised to $19 at Cowen
February 7, 2018 7:05 AM ESTCowen raised its price target on Array BioPharma (NASDAQ: ARRY) to $19.00 (from $17.00) while maintaining a Outperform rating.
Analyst Chris Shibutani commented, "F2Q18 results were highlighted by impressive pipeline updates including COLUMBUS data with greater than expected OS of 33.6 months for COMBO450 in BRAF-mutant... More
Array BioPharma (ARRY) PT Raised to $23 at Stifel
February 7, 2018 6:27 AM ESTStifel raised its price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $20.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "The disclosure of median OS data from the P3 COLUMBUS trial (encorafenib/binimetinib vs. vemurafenib in BRAF-mutant melanoma) provides further confirmation of the pharmacological... More
Array Biopharma (ARRY) Tops Q2 EPS by 6c
February 6, 2018 8:08 AM ESTArray Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $42.2 million versus the consensus estimate of $26.67 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
... More